Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Filanesib, KSP inhibitor · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Filanesib | EXPERIMENTAL | - |
| Carfilzomib + Filanesib | EXPERIMENTAL | Single agent + Carfilzomib arm. Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information. Filgrastim to be administered per the approved product prescribing information and institutional guidelines. |
| Carfilzomib | EXPERIMENTAL | Single agent arm. Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information. |
| Name | Type | Description |
|---|---|---|
| Filanesib, KSP (Eg5) inhibitor; intravenous | DRUG | multiple dose, single schedule |
| Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous | DRUG | standard of care |
| Carfilzomib, proteasome inhibitor; intravenous | DRUG | multiple dose, single schedule |
| Filanesib, KSP(Eg5) inhibitor; intravenous | DRUG | multiple dose, single schedule |
| Dexamethasone, steroid; oral or intravenous | DRUG | as indicated, per the carfilzomib prescribing information |
Key Inclusion Criteria: * Patients with confirmed multiple myeloma whose treatment history must include all of the following: 1. Received at least 2 prior lines of therapy (induction therapy and stem cell transplant ± maintenance are to be considered a single line of therapy). 2. Received at l...
Top 20 of 24 competitors
Filanesib is an investigational small molecule being studied for advanced multiple myeloma. It has been evaluated in Phase 2 clinical trials in patients with relapsed or refractory disease. It is not approved for commercial use and remains in clinical development.
Filanesib targets KIF11, also known as kinesin spindle protein or Eg5. It acts as an inhibitor of this target. KIF11 is involved in mitotic spindle formation, and inhibiting it disrupts cell division in dividing cells such as myeloma cells.
Pfizer, Inc. is the developer of filanesib. The company trades on the New York Stock Exchange under the ticker PFE. Pfizer has sponsored the Phase 2 clinical trials evaluating filanesib in advanced multiple myeloma.
Filanesib is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. Two Phase 2 trials have been completed, and no trials are currently active.
Filanesib has been studied in two completed Phase 2 trials. NCT02092922, the AfFIRM trial, evaluated filanesib in relapsed or refractory multiple myeloma with 154 patients across the United States and Europe. NCT01989325 studied filanesib with carfilzomib in 77 patients in the United States.
Yes, filanesib is also known as ARRY-520. It is additionally referred to as a KSP inhibitor or KSP (Eg5) inhibitor, and formulations described as intravenous. These names refer to the same investigational agent targeting KIF11.